BidaskClub upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a report issued on Thursday, BidAskClub reports.

A number of other research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Repligen from a hold rating to a strong-buy rating and set a $80.00 price target on the stock in a research note on Tuesday, May 14th. ValuEngine lowered shares of Repligen from a strong-buy rating to a buy rating in a research note on Thursday, April 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Repligen presently has a consensus rating of Buy and an average target price of $64.20.

Shares of Repligen stock opened at $69.47 on Thursday. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03. Repligen has a 12-month low of $42.80 and a 12-month high of $72.45. The company has a market cap of $3.39 billion, a price-to-earnings ratio of 84.45, a P/E/G ratio of 4.36 and a beta of 1.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.02. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The business had revenue of $60.63 million for the quarter, compared to analyst estimates of $55.09 million. During the same quarter in the prior year, the business posted $0.17 EPS. Repligen’s revenue for the quarter was up 35.3% compared to the same quarter last year. Research analysts forecast that Repligen will post 0.94 EPS for the current year.

In other news, CEO Anthony Hunt sold 14,550 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $59.63, for a total value of $867,616.50. Following the sale, the chief executive officer now owns 219,616 shares in the company, valued at $13,095,702.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jon Snodgres sold 6,467 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $58.54, for a total transaction of $378,578.18. Following the completion of the sale, the chief financial officer now owns 21,543 shares in the company, valued at approximately $1,261,127.22. The disclosure for this sale can be found here. Insiders sold 43,902 shares of company stock worth $2,627,287 in the last quarter. Company insiders own 1.70% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its stake in shares of Repligen by 314.6% in the first quarter. BNP Paribas Arbitrage SA now owns 8,984 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 6,817 shares during the period. Jane Street Group LLC increased its stake in shares of Repligen by 16.8% in the fourth quarter. Jane Street Group LLC now owns 11,427 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 1,645 shares during the period. Mascoma Wealth Management LLC acquired a new stake in shares of Repligen in the first quarter worth $41,000. Pier Capital LLC increased its stake in shares of Repligen by 14.3% in the first quarter. Pier Capital LLC now owns 141,097 shares of the biotechnology company’s stock worth $8,336,000 after acquiring an additional 17,672 shares during the period. Finally, Ardevora Asset Management LLP boosted its holdings in Repligen by 471.7% during the fourth quarter. Ardevora Asset Management LLP now owns 612,077 shares of the biotechnology company’s stock worth $32,281,000 after buying an additional 505,020 shares in the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: How is a buy-side analyst different from a sell-side analyst?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.